Robert Easton - Cepheid Independent Director
Director
Mr. Robert J. Easton is an Independent Director of Cepheid. Mr. Easton is cofounder and cochairman of Bionest Partners Inc. a strategic consulting firm specializing in evaluation and planning for pharmaceutical and medical device and diagnostic companies. Mr. Easton was director and Vice President of Apex Bioventures which he cofounded from 2007 to 2009. He was a director of CollaGenex Pharmaceuticals Inc. from 1994 until its sale in 2008. From 2000 to 2006 he was cofounder and Chairman of Easton Associates LLC and before that from 1996 to 2000 he was a Managing Director of IBM Healthcare Consulting. Mr. Easton spent 12 years with Union Carbide and Union Carbide Europe in multiple functional roles including marketing and engineering management roles in the Clinical Diagnostics business unit. Mr. Eastons analytical skills and broad experience as a strategic consultant to life sciences companies assist our Board in evaluating and refining our business strategies and commercial objectives. since 2002.
| Age | 68 |
| Tenure | 22 years |
| Phone | 408 541-4191 |
| Web | www.cepheid.com |
Cepheid Management Efficiency
The company has return on total asset (ROA) of (0.0746) % which means that it has lost $0.0746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.6296) %, meaning that it created substantial loss on money invested by shareholders. Cepheid's management efficiency ratios could be used to measure how well Cepheid manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 281.63 M in liabilities with Debt to Equity (D/E) ratio of 0.76, which is about average as compared to similar companies. Cepheid has a current ratio of 4.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cepheid until it has trouble settling it off, either with new capital or with free cash flow. So, Cepheid's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cepheid sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cepheid to invest in growth at high rates of return. When we think about Cepheid's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Takayuki Hosokai | Chiba Bank Ltd | N/A | |
| Margaret Zook | Univest Pennsylvania | 68 | |
| Kazuhiko Miyagi | Chiba Bank Ltd | N/A | |
| Michael Miles | Western Union Co | 58 | |
| Andrea Guthrie | Shoe Carnival | 45 | |
| Charles Tomm | Shoe Carnival | 68 | |
| Raymond OConor | Arrow Financial | 62 | |
| Kazuhiko Mizushima | Chiba Bank Ltd | 56 | |
| Shigenobu Sadachi | Chiba Bank Ltd | N/A | |
| John Murphy | Arrow Financial | 62 | |
| Tenee Casaccio | Arrow Financial | 52 | |
| Solomon | Western Union Co | 65 | |
| Hiroshi Seki | Chiba Bank Ltd | N/A | |
| Osamu Kimura | Chiba Bank Ltd | 60 | |
| Toshikazu Ohkubo | Chiba Bank Ltd | 58 | |
| Shoichi Hatano | Chiba Bank Ltd | 55 | |
| Junya Wakabayashi | Chiba Bank Ltd | N/A | |
| David Kruczlnicki | Arrow Financial | 65 | |
| Yuko Tashima | Chiba Bank Ltd | 64 | |
| John Carusone | Arrow Financial | 72 | |
| William Owens | Arrow Financial | 69 | |
Management Performance
| Return On Equity | -16.63 | |||
| Return On Asset | -0.0746 |
Cepheid Leadership Team
Elected by the shareholders, the Cepheid's board of directors comprises two types of representatives: Cepheid inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cepheid. The board's role is to monitor Cepheid's management team and ensure that shareholders' interests are well served. Cepheid's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cepheid's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Gutshall, Co-Founder, Director, Member of Nominating and Governance Committee and Member of Compensation and Organizational Devel. Committee | ||
| Robert Easton, Independent Director | ||
| Glenn Steele, Independent Director | ||
| Thomas Brown, Independent Director | ||
| Warren Kocmond, COO and Executive VP | ||
| Jacquie Ross, IR Contact Officer | ||
| Kerry Flom, Chief Regulatory Officer and Executive VP | ||
| Daniel Madden, Vice President Corporate Controller and Acting CFO | ||
| Michael Fitzgerald, Executive VP of Global HR | ||
| Peter Farrell, Executive VP of Worldwide Commercial Operations | ||
| David Persing, Executive Vice President Chief Medical and Technology Officer, Director | ||
| Scott Campbell, Corporate Vice President , Chief Regulatory Officer | ||
| Marc Haugen, Executive Vice President - Engineering and Operations | ||
| John Bishop, Chairman, CEO and Member of Equity Incentive Committee | ||
| Cristina Kepner, Lead Independent Director | ||
| Hollings Renton, Independent Director | ||
| Joseph Smith, Executive Vice President - Corporate Development, General Counsel |
Cepheid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cepheid a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -16.63 | |||
| Return On Asset | -0.0746 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (2.81) % | |||
| Current Valuation | 2.79 B | |||
| Shares Outstanding | 71.93 M | |||
| Shares Owned By Insiders | 1.74 % | |||
| Shares Owned By Institutions | 98.26 % | |||
| Number Of Shares Shorted | 2.61 M | |||
| Price To Earning | 910.67 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cepheid in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cepheid's short interest history, or implied volatility extrapolated from Cepheid options trading.
Pair Trading with Cepheid
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cepheid position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cepheid will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Eli Lilly could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eli Lilly when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eli Lilly - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eli Lilly and to buy it.
The correlation of Eli Lilly is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eli Lilly moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eli Lilly moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eli Lilly can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Cepheid information on this page should be used as a complementary analysis to other Cepheid's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Cepheid Stock
If you are still planning to invest in Cepheid check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cepheid's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |